[1] Lees AJ, Hardy J, Revesz T. parkinson's disease[J]. Lancet, 2009, 373(9680): 2055-2066. [2] Kilpeläinen T, Julku UH, Svarcbahs R, et al.Behavioural and dopaminergic changes in double mutated human A30P*A53T alpha-synuclein transgenic mouse model of parkinson's disease[J]. Scientific Reports, 2019, 9(1): 17382. [3] Abeliovich A, Rhinn H.Parkinson's disease: guilt by genetic association[J]. Nature, 2016, 533(7601): 40-41. [4] Wood H.Parkinson disease: peripheral α-synuclein deposits - prodromal markers for parkinson disease[J]. Nature Reviews. Neurology, 2016, 12(5): 249. [5] Olanow CW, Wakeman DR, Kordower JH.Peripheral alpha-synuclein and Parkinson's disease[J]. Movement Disorders, 2014, 29(8): 963-966. [6] Kim S, Kwon SH, Kam TI, et al. Transneuronal propagation of pathologic α-synuclein from the gut to the brain models parkinson's disease[J]. Neuron, 2019, 103(4): 627-641.e7. [7] Harvey BK, Wang Y, Hoffer BJ.Transgenic rodent models of parkins-on's disease[J]. Acta Neurochirurgica. Supplement, 2008, 101: 89-92. [8] Giasson BI, Duda JE, Quinn SM, et al.Neuronal alpha-synucl-einopathy with severe movement disorder in mice expressing A53T human alpha-synuclein[J]. Neuron, 2002, 34(4): 521-533. [9] Karpowicz RJ, Jr, Trojanowski JQ, Lee VMY. Transmission of α-synuclein seeds in neurodegenerative disease: recent develop-ments[J]. Laboratory Investigation, 2019, 99(7): 971-981. [10] Dehay B, Bourdenx M, Gorry P, et al.Targeting α-synuclein for treatment of parkinson's disease: mechanistic and therapeutic considerations[J]. The Lancet. Neurology, 2015, 14(8): 855-866. [11] Zhou TT, Zhang QS, Chen Y, et al.effects of bibenzyl compound(20C) from Gastrodia elata on MPTP/p-induced mice and mechanism[J]. Chinese Journal of Pharmacovigilance(中国药物警戒),2020, 17(11): 753-757,772. [12] Braak H, Del Tredici K, Rüb U, et al.Staging of brain pathology related to sporadic parkinson's disease[J]. Neurobiology of Aging, 2003, 24(2): 197-211. [13] Santos SF, de Oliveira HL, Yamada ES, et al. The gut and Parki-nson's disease-a bidirectional pathway[J]. Frontiers in Neurology, 2019, 10: 574. [14] Knudsen K, Krogh K, Ø stergaard K, et al. Constipation in Parkinson's disease: subjective symptoms, objective markers, and new perspectives[J]. Movement Disorders, 2017, 32(1): 94-105. |